Summary
Medtronic plc reported a net sales decrease of 3% for the three months ended October 28, 2022, compared to the same period last year, reaching $7.585 billion. This decline was primarily attributed to unfavorable currency impacts and ongoing supply chain challenges. Net income attributable to Medtronic significantly decreased to $427 million, or $0.32 per diluted share, from $1.311 billion, or $0.97 per diluted share, in the prior year's comparable quarter. This substantial decrease in profitability was largely due to a significant $764 million net tax charge related to a U.S. Tax Court opinion concerning historical income allocation. Despite the top-line and bottom-line declines, Medtronic's balance sheet remains strong with $4.8 billion in cash and cash equivalents and $6.6 billion in investments. The company also continued its strategic acquisitions, notably Intersect ENT for $1.2 billion and Affera, Inc. for $904 million, to bolster its Neuroscience and Cardiovascular segments, respectively. These acquisitions are expected to contribute to long-term growth, though they also resulted in significant goodwill and intangible asset additions. The company also highlighted progress on restructuring initiatives and continued share repurchases, with approximately $2.5 billion remaining under its authorized program.
Financial Highlights
55 data points| Revenue | $7.58B |
| Cost of Revenue | $2.54B |
| Gross Profit | $5.05B |
| SG&A Expenses | $2.62B |
| Operating Income | $1.40B |
| Interest Expense | $118.00M |
| Net Income | $435.00M |
| EPS (Basic) | $0.32 |
| EPS (Diluted) | $0.32 |
| Shares Outstanding (Basic) | 1.33B |
| Shares Outstanding (Diluted) | 1.33B |
Key Highlights
- 1Net sales declined 3% to $7.585 billion for the three months ended October 28, 2022, primarily impacted by unfavorable currency and supply chain issues.
- 2Net income attributable to Medtronic dropped significantly to $427 million ($0.32/share) from $1.311 billion ($0.97/share) year-over-year, largely due to a $764 million tax charge from a Tax Court ruling.
- 3The company made significant acquisitions: Intersect ENT for $1.2 billion and Affera, Inc. for $904 million, to strengthen its Neuroscience and Cardiovascular portfolios.
- 4Operating cash flow for the six months ended October 28, 2022, was $2.005 billion, a decrease from $3.061 billion in the prior year period, influenced by increased tax payments and inventory build-up.
- 5Free cash flow for the six months ended October 28, 2022, was $1.256 billion, down from $2.412 billion in the prior year, reflecting lower operating cash flow and higher capital expenditures.
- 6Medtronic's balance sheet remains robust with $4.8 billion in cash and cash equivalents and $6.6 billion in investments.
- 7The company continued its share repurchase program, with approximately $2.5 billion remaining under its authorized $6.0 billion program.